Q32 BIO INC.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
- Conditions
- Lupus Nephritis (LN)C3 (Complement Component 3) GlomerulopathyIgA Nephropathy
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06419205
- Locations
- 🇺🇸
Denver, Denver, Colorado, United States
🇺🇸Minneapolis, Minneapolis, Minnesota, United States
🇺🇸Las Vegas, Las Vegas, Nevada, United States
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
- Conditions
- Alopecia Areata
- Interventions
- Drug: bempikibart (ADX-914)
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06018428
- Locations
- 🇺🇸
Scottsdale, Arizona, Scottsdale, Arizona, United States
🇺🇸Fayetteville, Arkansas, Fayetteville, Arkansas, United States
🇺🇸Hot Springs, Arkansas, Hot Springs, Arkansas, United States
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05509023
- Locations
- 🇺🇸
Cahaba Dermatology Skin Health Center, Birmingham, Alabama, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
🇺🇸California Allergy and Asthma Medical Group- Los Angeles, Los Angeles, California, United States
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II
- Conditions
- Mucopolysaccharidosis II
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Homology Medicines, Inc
- Registration Number
- NCT05238324
- Locations
- 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸Yale Center for Clinical Investigation, New Haven, Connecticut, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Homology Medicines, Inc
- Target Recruit Count
- 3
- Registration Number
- NCT05222178
- Locations
- 🇺🇸
The Community Health Clinic, Topeka, Indiana, United States
🇺🇸Clinic for Special Children, Lancaster, Pennsylvania, United States
- Prev
- 1
- 2
- Next